Status: Not yet recruiting
A Multicenter Study of Active Specific Immunotherapy With OncoVax® in Patients With Stage II Colon Cancer
OncoVAX® is the first cancer therapy that both prevents cancer recurrence and addresses the diversity of cancer cells. In this pivotal randomized, multicenter Phase IIIb study in patients with Stage II colon cancer, OncoVAX is designed to use a patient's own cancer cells to mobilize the body's immune system to prevent the return of colon cancer following surgery.
Participants needed: 550
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Vaccinogen IncUpdated: Feb 2, 2026Locations: 1
Eligibility criteria
Patients must have Stage II (IIA = T3N0M0, IIB = T4aN0M0, IIC = T4bN0M0) disease... [+2]
Patients with prior radiation therapy or chemotherapy or a prior malignancy of a... [+1]